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■ Abstract
We report the case of a 21-year old man with a long-standing history of severe asthma and allergic rhinosinusitis who developed progressive 
worsening of dyspnea, wheezing, productive cough, and nasal obstruction, with little response to antibiotics and repeated short courses of 
oral corticosteroids. A diagnosis of allergic bronchopulmonary aspergillosis was made on the basis of a combination of clinical, laboratory 
and radiographic fi ndings. Treatment with oral methylprednisolone and itraconazole resulted in an improvement in symptoms, lung function 
and computed tomography results, as well as in a decrease in total serum immunoglobulin E. This case report highlights the importance of 
a high degree of clinical suspicion in order to diagnose and treat allergic bronchopulmonary aspergillosis in patients with a long-standing 
history of severe asthma as early as possible as this has a major impact on prognosis. It also highlights the effectiveness of itraconazole 
as adjunctive therapy to systemic corticosteroids in this condition.
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■ Resumen
Comunicamos un caso de un hombre de 21 años con una historia de larga evolución de asma grave y rinosinusitis alérgica que desarrolló 
un progresivo empeoramiento de la disnea, sibilancias, tos productiva, y obstrucción nasal, con pobre respuesta a antibióticos y tandas 
cortas de corticoides orales. Se realizó el diagnóstico de aspergilosis broncopulmonar alérgica en base a la combinación de los hallazgos 
clínicos, radiográfi cos y de laboratorio. EL tratamiento con Metilprednisolona oral e Itraconazol resultó en una mejora de los síntomas, de 
la función pulmonar, y de los resultados de la tomografía computarizada, así como un descenso en la IgE sérica total. Este caso resalta 
la importancia de un alto grado de sospecha clínica para diagnosticar y  tratar la aspergilosis broncopulmonar alérgica en pacientes con 
una historia de larga evolución de asma grave tan pronto como sea posible ya que el diagnóstico precoz tiene un gran impacto en el 
pronóstico.
También destaca la efectividad del Itraconazol como tratamiento adyuvante a los corticoides sistémicos en esta condición. 
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Introduction
 In allergic bronchopulmonary aspergillosis (ABPA), the 
inhalation of fungal spores and airway colonization by 
Aspergillus species can give rise to type I, type III, and 
possibly type IV hypersensitivity reactions, resulting in 
damage to bronchi and surrounding lung parenchyma such as 
bronchiectasis and pulmonary atelectasis [1,2].
 ABPA is most common in young adults, although it has 
been reported at both extremes of life, with pre-existing 
obstructive lung disease (namely asthma and cystic fi brosis). 
The prevalence of ABPA in patients with asthma ranges from 
0.25% to 28% [3-5]. Diagnosis is based on a combination of 
clinical, laboratory, and radiographic fi ndings, and a set of 
specifi c diagnostic criteria has been defi ned for patients with 
asthma [2]. In the absence of typical proximal bronchiectasis, 
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the condition is designated ABPA-seropositive as opposed to 
ABPA-central bronchiectasis [6]. 
 Delayed recognition of ABPA is not uncommon and can 
have important implications for long-term prognosis. ABPA 
progresses in 5 stages [7] and adequate treatment depends on 
the stage of disease [1,2]. The cornerstone of ABPA treatment 
is systemic corticosteroid therapy, although antifungal agents 
such as itraconazole are playing an emerging role in adjunctive 
therapy. 
 We report the case of a young man with a long-standing 
history of severe allergic asthma who developed progressive 
worsening of respiratory symptoms that did not respond to the 
usual rescue medication or repeated courses of antibiotics and 
systemic corticosteroids.
Case Description
 We describe the case of a 21-year-old Caucasian student who 
had had allergic asthma and rhinosinusitis since the age of 2 
years. Despite regular preventive treatment, he had experienced 
frequent asthma exacerbations during childhood, requiring 
systemic corticosteroids and admission to hospital. The 
respiratory symptoms were usually triggered by upper tract 
respiratory infections and exposure to house dust and grass 
pollen. Skin prick testing at the time was positive to different 
species of house dust mites and grass pollen allergen extracts. 
He underwent subcutaneous immunotherapy to treat house 
dust mite allergy for 5 years, leading to a clear improvement 
in symptoms and respiratory function, which was maintained 
throughout adolescence. Despite clinical and functional 





/forced vital capacity [FVC], 88.8%; midexpiratory fl ow 




, 63.7%), he 
was admitted to hospital for spontaneous pneumothorax and 
pneumomediastinum when he was 18 years old. This episode 
developed out of the context of an asthma exacerbation and 
had no bearing on the course of disease.
 At the age of 21 years, the patient started to develop recurrent 
episodes of dyspnea, exercise intolerance, productive cough, 
worsening of nasal obstruction, and purulent sputum and 
nasal discharge. He was prescribed antibiotics and oral 
corticosteroids, in addition to his usual inhaled therapy 
(salbutamol on an as-needed basis, fl uticasone 500 µg twice 
a day and salmeterol 50 µg twice a day), but there was little 
improvement. 
 Although the patient had a poor perception of symptoms, on 
clinical examination he presented nasal intonation and mouth 
breathing, increased anteroposterior thoracic diameter, and 
wheezing on pulmonary auscultation. Markedly inferior 
turbinate hypertrophy was also observed. Peak expiratory fl ow 
was 330 L/min (59% of predicted for his gender, age, height, 
and weight) and nasal inspiratory fl ow was 50 L/min.
 At this point, further investigations were performed. A full blood 
count revealed an increased eosinophil count  (7.6%, 1026/µL). 
Lymphocyte subsets, erythrocyte sedimentation rate, liver 
and renal function tests, as well as serum C-reactive protein, 
immunoglobulins (Ig) A, G, and M, IgG subclasses, and 
complement fractions were within normal limits. Total IgE 
was 1460 U/mL (previously 1200 U/mL). Antineutrophil 
cytoplasmic antibodies were negative. The sweat test result 
was unremarkable, as were results for serum α-1-antitrypsin, 
thyroid function, and serological studies (including HIV-1 and 
HIV-2 analyses). Arterial blood gas analysis showed hypoxemia 
(pO
2
, 79 mm Hg). Skin prick and intradermal testing were 
positive for Aspergillus fumigatus (5 mm and 20 mm wheal 
diameter after 20 minutes, respectively, with a positive 
control of 5 mm and a negative control of 0 mm). Previous 
skin prick testing had been negative for molds. Specifi c IgE 
to A fumigatus was elevated (34.7 kU/L) and specifi c IgG to 
the same mold was within the normal range (26.9 mgA/L). 
A fumigatus was identifi ed in a bronchial aspirate culture 
Figure 1. High-resolution pulmonary computed tomography scan. A, cystic and cylindrical bronchiectasis, micronodulary and tree-in-bud images are seen 
bilaterally. B, evident signs of improvement 1 year after initiation of treatment despite the persistence of bronchiectasis.
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 Total IgE Before 4 Months 6 Months 9 Months 12 Months
  Treatment
FVC    75.0% 85.8% 76.8% 96.1% 97.8%
FEV1    50.4% 58.0% 51.4% 88.5% 86.3%
FEV1/FVC    57.8% 58.0% 57.4% 79.1% 75.9%
FEF25-75    17.4% 18.5% 15.0% 56.3% 54.9%
R  139.9% 144% 131% 161% 63.4%
RV  202.2% 135% 117% NP  171.4%
BD (change in FEV1)     4.9% 6.73% 1.68% -1.1% 2.9%
CO Diffusion Normal Normal    NP  Normal    NP
Figure 2. Evaluation of total serum immunoglobulin (Ig) E, blood eosinophil count, and lung function before and after initiation of treatment (6 months 
of oral methylprednisolone including weaning doses and 4 months of itraconazole). FVC indicates forced vital capacity; FEV1, forced expiratory volume 
in 1 second; MEF25-75 midexpiratory fl ow between 25% and 75% of FVC; R, airway resistance; RV, residual volume; BD, bronchodilation test; CO, carbon 
monoxide; NP, not performed.
performed after bronchial endoscopy. Lung function testing 









, 17.4%) and an increase in FEV
1
 
after 200 µg of inhaled salbutamol of 4.9%. Carbon monoxide 
diffusing capacity was normal. Chest radiography revealed signs 
of hyperinfl ation (previous radiographs had been unremarkable), 
and a high-resolution computed tomography (CT) scan revealed 
central cylindrical and cystic bronchiectasis bilaterally (Figure 1). 
A nasal-sinus CT scan showed inferior and medium turbinate 
hypertrophy, ostiomeatal complex obstruction, and frontal and 
maxillary chronic sinusitis.
 The patient was prescribed oral methylprednisolone (1 mg/
kg/day) and itraconazole (200 mg/day), with no change 
to asthma and rhinitis treatments. Two weeks later, the 
methylprednisolone was progressively tapered down over the 
following 3 months until a dose of 10 mg was reached; this 
was then taken on alternate days for an additional 6 months. 
During this time, antifungal therapy was continued until 4 
months of treatment were completed.
 Close monitoring of the disease was performed throughout 
the treatment. Clinical improvement was evident with a 
reduction in dyspnea, wheezing, cough, and nasal obstruction, 
and improved exercise tolerance. This was accompanied by 
a reduction in total IgE and blood eosinophil count and an 
improvement in lung function parameters (Figure 2). Recovery 
was also noticeable on the CT scan 1 year after diagnosis 
(Figure 1). There was no clinical or laboratory evidence of 
adverse therapy-related effects. 
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Discussion
 We report the case of ABPA in a young adult with previously 
controlled severe asthma who developed an exacerbation of 
respiratory symptoms that did not respond to oral corticosteroids 
and in which oral itraconazole led to considerable clinical and 
functional improvement. This case highlights the role of 
antifungal agents in the treatment of ABPA. Treatment should 
not only target the hypersensitivity reaction (with systemic 
corticosteroids) but also aim to eradicate Aspergillus from the 
airways (using an antifungal agent such as itraconazole) [1].
 Early diagnosis of ABPA is essential for the prevention of 
recurrent exacerbations and progression to lung fi brosis [2,6]. 
However, it is not uncommon to diagnose ABPA at late stages 
of the disease [8]. In long-standing poorly-controlled and/or 
severe asthma, sometimes in association with pre-existing 
bronchiectasis, ABPA can be particularly diffi cult to detect and 
an extensive differential diagnosis has to be considered [9]. 
 In the reported case, the deterioration of respiratory symptoms 
and lung function parameters in a patient with previously 
controlled severe asthma could have been explained by 
several conditions. Nonadherence to therapy was denied by 
the patient and his inhalation technique was good. Bacterial 
infection of asthma-induced bronchiectasis and/or exacerbation 
of chronic rhinosinusitis seemed not to be the only issue, as 
there was no response to appropriate antibiotic treatment. Other 
conditions which can either mimic or occur simultaneously 
with uncontrolled asthma were also excluded based on 
history, clinical examination, and lung function fi ndings. 
These included chronic obstructive pulmonary disease, vocal 
cord dysfunction, psychological disturbances, chronic heart 
failure, gastro-oesophageal refl ux and occupational and drug-
induced respiratory diseases. Cystic fi brosis, primary ciliary 
dyskinesia, α-1-antitrypsin defi ciency, thyroid disease and 
Churg-Strauss syndrome were ruled out based on laboratory 
testing, as were primary immunodeficiencies (namely 
antibody defi ciencies) and secondary immunodefi ciencies 
such as HIV infection. The detection of impaired immunity is 
important not only as a differential diagnosis per se but also 
within the context of Aspergillus-induced diseases, as ABPA 
occurs in immunocompetent hosts, in whom the response of 
polymorphonuclear leucocytes and alveolar macrophages is 
not defective [1,2]. On the contrary, immunodefi cient patients 
are more likely to have invasive aspergillosis [10,11]. 
 The presence of asthma, central bronchiectasis on the CT 
scan, positive skin prick and intradermal tests to A fumigatus, 
increased total serum IgE and specifi c IgE to A fumigatus, 
combined with pulmonary infi ltrates in chest radiography, 
peripheral blood eosinophilia and a positive sputum culture 
for A fumigatus enabled the diagnosis of ABPA to be made 
as a complication of pre-existing controlled severe allergic 
asthma. 
 As clearly demonstrated by the clinical improvement observed, 
the decrease in serum total IgE, and the improvement in CT and 
lung function results, the patient responded well to treatment 
with oral itraconazole and methylprednisolone following 
failure to respond to repeated courses of oral corticosteroids in 
the same dose range. In fact, oral itraconazole has been shown 
to be effective as an adjunctive therapy for ABPA, allowing a 
reduction in the need for corticosteroids [12-14]. This therapy 
has been seen to reduce exacerbations, improve laboratory and 
lung function parameters, and prevent disease progression [15]. 
It has an antiinfl ammatory effect, which reduces eosinophilic 
airway infl ammation and systemic immune activation [16]. 
However, there are concerns regarding this treatment in 
relation to resistance, cost, drug interactions, and toxicity 
(such as rhabdomyolysis, adrenal insuffi ciency, and hepatitis). 
Moreover, the long-term effect of itraconazole on lung function 
is still unknown [17]. In our patient, no adverse events had 
developed at the time of writing and different laboratory 
parameters refl ecting immunological mechanisms of ABPA, 
such as total and specifi c IgE, eosinophil count and cutaneous 
reactivity to Aspergillus, decreased with this treatment. 
Corticosteroids are the fi rst-line therapy for ABPA, reducing 
the immune response mounted to the presence of Aspergillus 
in the airways. Nevertheless, long-term systemic corticosteroid 
therapy is not recommended as there is no evidence that it 
prevents the progression of lung destruction [18] and it may 
be ineffective in end-stage fi brosis.
 In the future, our patient will continue to be monitored for 
clinical deterioration as relapses in ABPA are common, despite 
initial response to therapy. The most useful tools, used in 
combination, to monitor the course of disease, assess response 
to therapy, and identify exacerbations and relapses are the 
evaluation of symptoms, chest radiography or high resolution 
CT [19], total serum IgE, and lung function tests [1]. 
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